Drugs / VMX-C001
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06517563 | Aug → Dec 2024 | blood coagulation disease | VarmX B.V. | Completed | No outcome recorded |
| Phase 1 | NCT06372483 | Feb → Aug 2024 overdue | blood coagulation disease | VarmX B.V. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05152420 | Oct 2021 → Feb 2023 | blood coagulation disease | VarmX B.V. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07288489 | Mar 2026 → Jan 2029 expected | blood coagulation disease | VarmX B.V. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMX-C001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06517563 ↗ |
| Modality | Protein / enzyme biologic | “VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs” NCT05152420 ↗ |
| Route | Intravenous | “Intravenously administered VMX-C001” NCT05152420 ↗ |